SAT0421 Reduction in Fatigue in Patients with Active Ankylosing Spondylitis: Results of Two Phase 3 Studies of Secukinumab
BackgroundPatients with active ankylosing spondylitis (AS) experience fatigue which frequently leads to reduced health-related quality of life (HRQoL). Secukinumab (SEC) treatment results in rapid improvements in signs and symptoms, physical functioning and HRQoL in patients with active AS versus pl...
Saved in:
Published in | Annals of the rheumatic diseases Vol. 75; no. Suppl 2; p. 823 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group LTD
01.06.2016
|
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!